UCB stock carries first half drug sales into October

Published on 10/06/2026 at 16:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB stock was EUR 199.90 on October 6, 2026, 31.0 percent below its 52-week high. H1 2026 sales included EUR 1.52 billion from BIMZELX.

Geometrisches Bauhaus-Poster mit Kreisen, Dreiecken und dem Schriftzug BIOPHARM in Primärfarben — UCB S.A., ISIN BE0003739530, illustriert als geometrisches Bauhaus-Poster mit Sektor-Kürzel BIOPHARM und Molekülformen, Illustration mit AI erstellt.

UCB stock was trading at EUR 199.90 on Euronext Brussels on October 6, 2026, at 4:34 p.m. CEST, down 0.50 percent from the previous close. The price stood 31.0 percent below its 52-week high of EUR 289.50, putting the companys latest drug sales alongside a materially lower market valuation.

BIMZELX sales reach EUR 1.52 billion

According to UCB investor materials updated October 1, 2026, BIMZELX generated EUR 1.52 billion in sales during the first half of 2026. The company also listed EUR 954 million in H1 2026 sales for CIMZIA, EUR 239 million for FINTEPLA and EUR 192 million for RYSTIGGO.

The product mix gives investors a clearer growth map than the share price alone. BIMZELX is the largest of the named growth drivers, while the established portfolio still contributes substantial revenue, including EUR 327 million from BRIVIACT and EUR 216 million from KEPPRA in H1 2026, according to UCB.

CIMZIA designation opens a new path

On September 9, 2026, the U.S. Food and Drug Administration granted CIMZIA Breakthrough Therapy Designation for preventing placenta-mediated adverse pregnancy outcomes in pregnant women with antiphospholipid syndrome and lupus anticoagulant, UCB reported.

The regulatory status supports faster development and review, but the same company release states that CIMZIA is not approved for this use and that safety and efficacy have not been established. That distinction matters because the designation expands the development opportunity without representing a commercial approval.

The stock sits 31.0 percent below its high

UCB had a market capitalization of EUR 38.1 billion on October 6, 2026, while trading volume reached 44,925 shares. Its intraday range was EUR 198.75 to EUR 204.30, leaving the last price near the lower end of the session range.

For investors, the central question is whether the growth drivers can offset the valuation reset already visible in the 52-week comparison. UCB combines H1 2026 sales momentum with regulatory optionality, while the share price remains well below EUR 289.50.